Exagen Inc. (XGN)
NASDAQ: XGN · Real-Time Price · USD
6.66
+0.08 (1.22%)
At close: Aug 14, 2026, 4:00 PM EDT
6.50
-0.16 (-2.40%)
After-hours: Aug 14, 2026, 7:49 PM EDT
Exagen Employees
As of December 31, 2025, Exagen had 220 total employees, including 216 full-time and 4 part-time employees. The number of employees increased by 5 or 2.33% compared to the previous year.
Employees
220
Change (1Y)
5
Growth (1Y)
2.33%
Revenue / Employee
$323,282
Profits / Employee
-$86,014
Market Cap
161.34M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 220 | 5 | 2.33% | 216 | 4 |
| Dec 31, 2024 | 215 | 36 | 20.11% | 209 | 6 |
| Dec 31, 2023 | 179 | -25 | -12.25% | 174 | 5 |
| Dec 31, 2022 | 204 | -18 | -8.11% | 199 | 5 |
| Dec 31, 2021 | 222 | 39 | 21.31% | 219 | 3 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2013 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Myriad Genetics | 2,700 |
| OPKO Health | 2,275 |
| Fulgent Genetics | 1,315 |
| Castle Biosciences | 1,002 |
| Burning Rock Biotech | 667 |
| MDxHealth | 364 |
| Freenome | 363 |
| Biodesix | 334 |
XGN News
- 5 days ago - Exagen Transcript: Canaccord Genuity's 46th Annual Growth Conference - Transcripts
- 11 days ago - Exagen price target raised to $9 from $8 at BTIG - TheFly
- 11 days ago - Exagen price target raised to $12 from $8 at B. Riley - TheFly
- 11 days ago - Exagen price target raised to $10 from $8 at TD Cowen - TheFly
- 11 days ago - Exagen price target raised to $9 from $8 at Canaccord - TheFly
- 12 days ago - Exagen raises FY26 revenue view to $72M-$75M from $70M-$73M - TheFly
- 12 days ago - Exagen reports Q2 EPS (13c), consensus (17c) - TheFly
- 12 days ago - Exagen Earnings Call Transcript: Q2 2026 - Transcripts